- and cis-diamminedichloroplatinum (II) in the
treatment of
advanced nonsquamous cell head and neck cancer". Cancer. 52 (11): 2007–10. doi:10...
- of
pemetrexed and
itraconazole as second-line
therapy for
metastatic nonsquamous non-small-cell lung cancer".
Journal of
Thoracic Oncology. 8 (5): 619–623...
- for
patient with
squamous cell NSCLC, or
pemetrexed for
patients with
nonsquamous disease.
Atezolizumab was
better tolerated than chemotherapy. In the...
-
Motesanib was
originally investigated for
effectiveness against advanced nonsquamous non-small-cell lung
cancer (NSCLC), with
Phase II
trials indicating an...
- own
Alimta (pemetrexed) and
platinum chemotherapy for
newly diagnosed nonsquamous non-small cell lung cancer. In July 2021, the
company announced it would...
- Brandwein-Gensler,
Margaret S.; Mahadevia, Panna; Gnepp,
Douglas R. (2009). "5 -
Nonsquamous Pathologic Diseases of the Hypopharynx, Larynx, and Trachea". Diagnostic...
- squamous-cell non-small cell lung cancer, or
pemetrexed for
those with
nonsquamous disease. The
overall survival was 17.1, 15.7, and 14.9 months, respectively...
-
Administration (FDA)
approved bevacizumab for use in first-line
advanced nonsquamous non-small cell lung
cancer in
combination with carboplatin/pa****axel...
- 3 $834 $628 $350.2
pemetrexed Alimta Locally advanced or
metastatic nonsquamous non-small cell lung
cancer (NSCLC) Eli
Lilly & Co. $1,154.7 $854 $611...
- for
patient with
squamous cell NSCLC, or
pemetrexed for
patients with
nonsquamous disease. The
overall survival was 17.1, 15.7 and 14.9 months, respectively...
